Eli Lilly and Company (NYSE:LLY) Stock Rating Reaffirmed by Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Eli Lilly and Company (NYSE:LLY) in a research report sent to investors on Monday, Benzinga reports. Cantor Fitzgerald currently has a $885.00 price target on the stock.

Several other equities analysts have also recently weighed in on the company. JPMorgan Chase & Co. raised their price target on Eli Lilly and Company from $850.00 to $900.00 and gave the company an overweight rating in a report on Wednesday, May 1st. Jefferies Financial Group raised their price target on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a buy rating in a report on Monday, June 24th. Erste Group Bank upgraded Eli Lilly and Company from a hold rating to a buy rating in a report on Wednesday, April 3rd. TheStreet upgraded Eli Lilly and Company from a c+ rating to a b rating in a report on Friday, March 8th. Finally, Citigroup lifted their target price on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a buy rating in a report on Tuesday, April 2nd. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and a consensus price target of $812.72.

Eli Lilly and Company Stock Down 0.9 %

Shares of LLY opened at $898.10 on Monday. The business’s 50 day moving average is $821.29 and its 200 day moving average is $745.62. The company has a market capitalization of $853.56 billion, a PE ratio of 132.27, a price-to-earnings-growth ratio of 1.97 and a beta of 0.41. Eli Lilly and Company has a 12-month low of $434.34 and a 12-month high of $918.50. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.05. The company had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm’s quarterly revenue was up 26.0% on a year-over-year basis. During the same quarter last year, the company earned $1.62 EPS. Research analysts expect that Eli Lilly and Company will post 13.76 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.58%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 92,563 shares of the business’s stock in a transaction on Friday, May 24th. The stock was sold at an average price of $809.21, for a total value of $74,902,905.23. Following the completion of the transaction, the insider now directly owns 98,556,247 shares of the company’s stock, valued at approximately $79,752,700,634.87. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, major shareholder Lilly Endowment Inc sold 92,563 shares of the business’s stock in a transaction on Friday, May 24th. The stock was sold at an average price of $809.21, for a total value of $74,902,905.23. Following the completion of the transaction, the insider now directly owns 98,556,247 shares of the company’s stock, valued at approximately $79,752,700,634.87. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Johna Norton sold 7,056 shares of the business’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.38, for a total value of $5,781,545.28. Following the completion of the transaction, the executive vice president now directly owns 25,428 shares of the company’s stock, valued at $20,835,194.64. The disclosure for this sale can be found here. Insiders sold a total of 858,742 shares of company stock valued at $735,573,781 in the last ninety days. Corporate insiders own 0.13% of the company’s stock.

Institutional Trading of Eli Lilly and Company

Several large investors have recently added to or reduced their stakes in LLY. Norges Bank purchased a new stake in Eli Lilly and Company during the 4th quarter valued at about $5,992,890,000. International Assets Investment Management LLC grew its stake in Eli Lilly and Company by 61,268.8% during the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after purchasing an additional 7,330,815 shares during the last quarter. Swedbank AB purchased a new stake in Eli Lilly and Company during the 1st quarter valued at about $932,797,000. Sapient Capital LLC purchased a new stake in Eli Lilly and Company during the 4th quarter valued at about $682,139,000. Finally, Vanguard Group Inc. boosted its stake in shares of Eli Lilly and Company by 1.6% in the first quarter. Vanguard Group Inc. now owns 72,745,011 shares of the company’s stock worth $56,592,709,000 after buying an additional 1,133,810 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.